The operational challenges of diagnosing parasitic infections in resource-constrained settings
A practical perspective for hospital directors, clinic managers and laboratory leaders: how to organise reliable diagnostic services when staff, supplies, infrastructure and budgets are limited.
For a medical institution, diagnostic capacity is more than a list of tests. It is the ability to obtain a suitable specimen, examine it correctly, return an interpretable result and ensure that somebody acts on it. WHO’s laboratory quality guidance treats these pre-analytical, analytical and post-analytical stages as one process, with failures at any stage requiring investigation and corrective action. 1
The scale of parasitic disease makes this an important management responsibility. WHO estimated 282 million malaria cases worldwide in 2024. Separately, at least 253.7 million people required preventive treatment for schistosomiasis that year. These indicators measure different things—malaria illness and eligibility for preventive treatment—and should not be added together or interpreted as a facility’s testing demand. Local caseloads and national policies must guide service planning. 2 3
The operational difficulty is that different parasites require different specimens, methods and response times. A manager cannot solve every gap by purchasing another microscope or introducing a rapid test. The more useful starting point is to decide which diagnostic pathways the institution can sustain, which require external support and where delays create the greatest clinical risk.
1. Build a defined diagnostic service, rather than promise a universal parasite screen
The phrase “parasite test” can conceal major differences. WHO describes urine filtration for urogenital schistosomiasis, stool examination for intestinal schistosomiasis and circulating cathodic antigen testing in areas with Schistosoma mansoni transmission. A method appropriate for one species and use case is not automatically suitable for another. 3
Other infections expose the limitations of a generic stool request. CDC notes that Cryptosporidium testing has historically required a specific request in many laboratories. Its detection may involve special staining, antigen methods or molecular testing. A routine examination does not necessarily include these procedures. 4
Identification also has limits. Entamoeba histolytica, E. dispar and E. moshkovskii cannot be distinguished by morphology alone, according to CDC. Reporting microscopy as if it had established a species-level diagnosis can therefore overstate what the laboratory has demonstrated. 5
Managers should agree a short service catalogue with clinicians and laboratory staff: the infections addressed, available methods, specimen requirements, reporting limitations and referral options. This is a proposed application of the distinctions above. It need not be technologically elaborate; its purpose is to prevent a requested investigation from being mistaken for a comprehensive exclusion of all parasitic disease. 3 4 5
For example, a persistent-diarrhoea pathway should specify when additional testing is considered, rather than leave the clinician to assume that “stool microscopy negative” includes Cryptosporidium. The catalogue should describe the actual local service, not reproduce the capabilities of a better-equipped reference centre. 4
2. Recognise the limitations of negative results
Sensitivity depends on the method and infection intensity. A 2014 meta-analysis of soil-transmitted helminth diagnostics estimated sensitivity of double-slide Kato–Katz at 74–95% across the three parasite groups studied in high-intensity infections, falling to 53–80% in low-intensity settings. These ranges are historical pooled estimates, not guaranteed performance values for an individual laboratory. They demonstrate why a negative result cannot always be interpreted independently of clinical context. 6
Specimen repetition can improve detection, but imposes work and costs. CDC’s stool-collection guidance advises that repeat collection may be needed after an initial negative examination and, where possible, three specimens collected at intervals of two to three days should be examined. This is guidance for diagnostic stool examination, not an instruction to request three specimens for every patient or every testing platform. 7
A plausible management response is to establish clinician-approved escalation criteria for persistent symptoms, relevant exposures and high-risk patients. Repeat testing and referral should be targeted to situations in which they may change care. This preserves limited capacity while recognising that a single negative test has a defined evidential limit. 6 7
Strongyloidiasis deserves a distinct pathway. CDC describes traditional stool examination as insensitive and identifies specialised techniques, including Baermann concentration and agar plate culture. It also notes limitations of serology, including cross-reactivity and difficulty distinguishing past from current infection. Simply repeating the institution’s usual “ova and parasites” procedure may not address these limitations. 8
3. Treat specimen collection and timing as core clinical operations
CDC recommends collecting stool into a clean, dry, leakproof container without contamination by urine, water or soil, followed by prompt examination, processing or appropriate preservation. For managers, this means budgeting for collection containers and giving patients understandable instructions before they leave the consultation. 7
Timing is particularly important for hookworm detection. In a study on Pemba Island, Tanzania, researchers investigated storage and processing effects in 488 stool specimens from schoolchildren. Hookworm egg counts on prepared Kato–Katz slides declined with time; after 24 hours they were close to zero irrespective of slide storage condition. The study discusses the recommended 30–60-minute reading window for hookworm. Its findings should not be generalised to every parasite or stool method. 9
The operational response is to coordinate collection, preparation and reading. For non-urgent investigations, collection appointments can be aligned with staffed laboratory hours. Slide preparation should match reading capacity, rather than create a queue that cannot be examined within the required interval. An urgent clinical pathway must remain available when a scheduled collection would be inappropriate. 9
Referral creates another constraint: preservation must match the destination test. CDC’s molecular-diagnosis guidance warns that some commonly used fixatives, including formalin, are unsuitable for its stool molecular workflows. Before introducing a referral route, the sending and receiving laboratories should agree containers, preservatives, transport conditions and acceptance criteria. A specimen preserved for microscopy should not automatically be assumed suitable for PCR. 10
4. Protect urgent care while planning routine workload
Malaria and routine helminth investigations cannot share a single undifferentiated queue. WHO recommends prompt microscopy or rapid diagnostic testing for suspected malaria, with assessment for other causes of fever when a quality-assured test is negative. A negative malaria result must lead to a clinical decision, rather than simply end the investigation. 11
Emergency exceptions also matter. WHO guidance states that absence or delay of parasitological confirmation should not postpone immediate antimalarial treatment in suspected severe malaria. Managers should ensure that emergency protocols and diagnostic escalation are agreed by clinical leaders and aligned with current national guidance. 12
Strongyloides risk illustrates why prioritisation must extend beyond fever. CDC advises particular attention to patients receiving or about to receive corticosteroids or other immunosuppressants, especially where exposure history is relevant. The institutional implication is a documented risk-assessment and testing/referral pathway before planned immunosuppression, with urgent decisions remaining under clinical supervision. 13
For routine staffing, WHO’s Workload Indicators of Staffing Need method offers a useful framework: estimate workload using activity-specific time standards. A stool examination, blood-film assessment, quality-control activity and referral preparation are different tasks. Counting all of them as interchangeable “tests” can produce a misleading staffing picture. 14
A modest first step is a short time-and-workload review, including supervision, cleaning, stock management and leave coverage. This is a proposed local adaptation of workload-based planning. Where recruitment is unavailable, the findings can support revised collection hours, protected microscopy sessions or negotiated referral support. 14
5. Build competence and quality assurance into the working week
Quality assurance needs protected time. WHO’s malaria microscopy manual treats slide cross-checking as complementary to competence assessment, retraining, supervision and proficiency testing. It also stresses that detecting poor performance must lead to correction. Sending slides away without receiving feedback is therefore an incomplete quality system. 15
A feasible approach is to negotiate external support with a district or reference laboratory, using a manageable review process and a named person responsible for acting on findings. The workload should be realistic: WHO’s manual cautions against increasing cross-checking volumes beyond the capacity to examine them accurately. Malaria procedures should not simply be copied unchanged for every stool parasite; relevant reference expertise is needed. 15
Rapid tests also require supervision. In March 2025, WHO warned that faint malaria RDT lines can be misread as negative. Its notice emphasised following product instructions, correct blood transfer, appropriate storage and reading any test line as positive, however faint, within the prescribed interpretation procedure. It also called for updated training and supervision. 16
Managers can incorporate these issues into brief observed competency checks and review of unusual results. Task sharing should remain within national rules and demonstrated competence; the relative simplicity of an RDT does not remove responsibility for correct performance and interpretation. 16
6. Secure the minimum operating environment
Infrastructure limitations are measurable. WHO’s October 2026 electricity fact sheet reports that only around half of hospitals in sub-Saharan Africa have reliable electricity. The underlying assessment uses national survey data from 2015–2022, so it describes a documented structural constraint rather than a newly measured 2026 facility census. 17
Managers should map which diagnostic activities fail during an outage and specify a fallback for each. Battery-supported equipment may be appropriate for selected functions, but battery replacement, charging and maintenance must be included in the plan. A backup device is useful only if it can perform the required validated method under the conditions available. This is a planning recommendation arising from the documented electricity gap. 17
Water, hygiene and waste services deserve equal attention. WHO and UNICEF reported that, globally in 2023, 1.1 billion people were served by healthcare facilities without basic water services and 2.8 billion by facilities without basic waste services. These are global estimates, not figures specific to African parasitology laboratories. 18
WHO’s laboratory biosafety manual recommends controls based on an assessment of the actual activities and risks. Institutions should therefore establish safe specimen handling, cleaning, waste arrangements and appropriate protective measures before expanding testing. The point is to select proportionate controls, not assume that every procedure needs expensive containment—or that limited resources justify unsafe handling. 19
Microscope care is another practical investment. WHO provides a dedicated use-and-maintenance procedure for malaria laboratories. Managers can translate it into assigned responsibilities, cleaning supplies and a servicing route, with downtime recorded rather than left as an informal staff problem. 20
7. Manage stocks around continuity of testing
Procurement can undermine a service even when funding has been secured. WHO’s IVD procurement guidance warns about products mismatched to users’ skills, intended specimens or operating conditions, and about failures to anticipate reagent stability and remaining shelf life. Selection should therefore include laboratory staff who understand the complete workflow. 21
Inventory control can begin with simple stock cards. WHO’s stepwise laboratory-quality tool recommends identifying essential items, setting minimum and maximum quantities based on use, defining supply specifications and recording suppliers. It specifically highlights minimum remaining shelf life at delivery. This makes consumables management a defined responsibility rather than an emergency activity when the last box is opened. 22
A practical reorder calculation is expected consumption during delivery lead time plus a buffer reflecting uncertainty. This is an illustrative management rule, not a universal WHO stock threshold. The buffer should be reviewed against expiry risk, storage space, seasonal demand and cash availability. An institution with unpredictable deliveries needs a different arrangement from one with reliable weekly replenishment. 22
Storage requirements remain product-specific. WHO’s malaria RDT procurement guidance includes temperature stability, transport, stock forecasting and supplier support, and recommends high thermal stability for very hot environments. Managers should monitor actual storage conditions against the selected product’s instructions, rather than assume that all rapid tests tolerate the same temperature range. 23
8. Use referral networks where on-site capacity cannot be sustained
A small institution does not need to perform every specialised investigation itself. WHO’s national laboratory-system benchmarks support mapping existing capacity, defining referral networks, training staff in specimen handling and monitoring transport integrity and turnaround time. They also encourage using existing transport systems more broadly where capacity is limited. 24
For a facility manager, the proposed operational package is straightforward: a named receiving laboratory, agreed test menu, specimen requirements, transport arrangements, responsibility for payment and a route for returning results. Urgent cases need an escalation route distinct from scheduled non-urgent transport. Shared transport is only suitable when packaging, timing and conditions remain compatible with every specimen carried. 24
The trade-off is between sustainable expertise and delay. Centralising a rarely used method may avoid maintaining underused local capacity, but it is only a workable solution if specimens arrive fit for testing and results return in time to influence care. A referral agreement should therefore describe the complete service, not merely identify an address. 24
Molecular testing provides a useful example. CDC describes PCR as an option where stool parasite identification is uncertain, alongside specific collection and shipping requirements. A referral route may consequently be more plausible than installing PCR locally without the required specimen workflow. Whether it is preferable must be established from local demand, turnaround and costs. 10
9. Budget for the diagnostic pathway
Historical costing evidence illustrates why purchase price is insufficient. A 2015 study of school-based S. mansoni detection in western Kenya estimated total per-person costs of US$6.89 for single-stool Kato–Katz, US$17.54 for triplicate-stool Kato–Katz and US$7.26 for point-of-care CCA. The estimates included specimen collection, analysis and treatment delivery for positive cases. They are historical programme costs, not current hospital tariffs or evidence that the methods are clinically interchangeable. 25
For managers, the lesson is methodological: compare the resources needed to deliver the intended diagnostic outcome. Include collection, staff time, controls, transport, equipment, waste and repeat investigations. WHO’s malaria procurement guidance similarly requires budgeting for operating expenses such as training, distribution, supervision and quality assurance, beyond the RDT purchase itself. 23 25
Patient affordability belongs in the same review. WHO reports that out-of-pocket payments represented 34% of current health expenditure in its African Region in 2022. This is a regional health-financing indicator, not a parasitology-specific charge, but it reinforces the importance of assessing what patients must pay to complete an investigation. 29
Managers could examine whether patients need separate visits for instructions, containers, collection and results, and combine steps where specimen requirements and clinical safety allow. Clear appointment information and an agreed way to communicate results may be more feasible initially than introducing another testing platform. These are proposed service-design responses, not proven savings estimates. Remote communication should use patient-approved channels and protect confidentiality; it also needs an alternative for patients without reliable phone access. Where repeat sampling is clinically indicated, reducing unnecessary administrative visits should support that pathway rather than replace it. 7 29
Budget choices should also distinguish individual care from public-health surveillance. WHO’s schistosomiasis guideline addresses preventive-treatment thresholds and programme decisions as well as diagnostic assessment. A hospital investigation and a prevalence survey serve different purposes and should not automatically share the same testing strategy. Population treatment policy does not remove the need to assess a symptomatic patient appropriately. 26
A feasible purchasing decision should specify the recurrent funding source and the fallback if supplies or technical support cease. Comparing a strengthened existing service with referral and new equipment offers a more credible decision than assuming the newest platform must be the most affordable operational option. 21 25
10. Measure whether results reach clinical decisions
WHO’s laboratory-quality implementation tool recommends monitoring critical points across the testing process rather than trying to measure everything. Specimen rejection is one suggested indicator; rising rejection should trigger investigation and corrective action. Its process-management checklist also addresses test-specific turnaround times and action when delays increase. 1 27
A manager could begin with the following dashboard. These are proposed operational measures, to be adapted locally, rather than universal performance thresholds.
| Measure | Practical definition | Management question |
|---|---|---|
| Specimen rejection | Rejected specimens divided by specimens received, with reasons | Are collection instructions or transport failing? |
| Turnaround compliance | Results issued within the agreed test-specific interval divided by results issued | Where does the queue develop? |
| Stock-out days | Days an essential test cannot be offered because an item is unavailable | Are ordering or delivery arrangements adequate? |
| Invalid results | Invalid runs divided by runs performed, separated by product and lot | Is training, storage or product performance involved? |
| Referral completion | Referred investigations with a returned report divided by investigations sent | Does the external pathway function? |
| Clinical acknowledgement | Reports requiring follow-up with documented receipt by the responsible team | Who owns the next action? |
The dashboard extends WHO’s quality-indicator approach to local management needs. It can begin with a paper register or spreadsheet; the immediate requirement is consistent definitions and responsibility for corrective action. Avoid rewarding low rejection rates alone: accepting unsuitable specimens to improve a statistic would undermine the purpose of quality monitoring. 1 27
11. Improve in stages, and assess innovation against operational needs
A practical implementation sequence can fit within an initial three-month improvement cycle. This is a suggested management approach based on the quality, staffing, inventory and referral frameworks above, not a validated intervention with guaranteed results. 14 22 24 27
During the first month, map existing pathways, review recent failures and agree the essential service catalogue. Establish who owns specimen collection, stock monitoring, quality follow-up and results communication. In the second month, address the most consequential gaps: collection timing, urgent cover, critical supplies and a functioning referral agreement. In the third, review the dashboard with clinical and laboratory teams and decide which remaining bottleneck justifies additional expenditure.
DIDIDI’s planned activities are relevant to this longer-term assessment. Its work programme includes field evaluation of digital diagnostics, human-centred design with frontline users in Uganda and Kenya, and health-economic and deployment assessment. These are research objectives, not evidence that the proposed tools are already validated for routine adoption. 28
Managers considering such innovations should ask for evidence of accuracy in the intended population, operator training needs, end-to-end turnaround, maintenance requirements and recurrent costs. They should also ask how errors are reviewed and how the device fits existing reporting systems. These questions reflect the operational constraints throughout this article. The goal is a service that remains dependable when staffing is thin, deliveries are delayed and patients cannot readily return—not simply a broader list of technologies.
References
Sources checked on 2 November 2026. Clinical pathways must follow applicable national guidance. Local management proposals and the dashboard are derived from the cited frameworks; they are not presented as independently evaluated interventions. Historical study costs and diagnostic-performance estimates are identified as such.
-
WHO. Laboratory Quality Stepwise Implementation: Identify and start monitoring critical parameters—quality indicators. extranet.who.int/lqsi/content/identify-and-start-monitoring-critical-parameters-quality-indicators
-
WHO (2025). World malaria report 2025. Estimates for 2024. www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2025
-
WHO (2026). Schistosomiasis. Fact sheet, 23 February 2026. www.who.int/news-room/fact-sheets/detail/schistosomiasis
-
CDC (2025). Clinical Testing and Diagnosis for Crypto. 27 May 2025. www.cdc.gov/cryptosporidium/hcp/diagnosis-testing/
-
CDC DPDx. Amebiasis. Laboratory diagnosis and morphological limitations. www.cdc.gov/dpdx/amebiasis/
-
Nikolay B, Brooker SJ, Pullan RL (2014). Sensitivity of diagnostic tests for human soil-transmitted helminth infections: a meta-analysis in the absence of a true gold standard. International Journal for Parasitology, 44, 765–774. pubmed.ncbi.nlm.nih.gov/24992655/
-
CDC DPDx. Stool Specimens—Specimen Collection. www.cdc.gov/dpdx/diagnosticprocedures/stool/specimencoll.html
-
CDC (2026). Clinical Overview of Strongyloides. 11 February 2026. www.cdc.gov/strongyloides/hcp/clinical-overview/
-
Bosch F et al. (2021). Diagnosis of soil-transmitted helminths using the Kato–Katz technique: What is the influence of stirring, storage time and storage temperature on stool sample egg counts? PLOS Neglected Tropical Diseases, 15, e0009032. journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0009032
-
CDC DPDx (2020). Stool Specimens—Molecular Diagnosis. Collection and preservation requirements for CDC workflows; receiving-laboratory instructions remain decisive for referrals. www.cdc.gov/dpdx/diagnosticprocedures/stool/moleculardx.html
-
WHO Global Malaria Programme. Diagnostic testing. www.who.int/teams/global-malaria-programme/case-management/diagnosis/
-
WHO (2026). WHO guidelines for malaria. Current consolidated guideline, 10 September 2026. www.who.int/publications/i/item/guidelines-for-malaria/
-
CDC (2024). Clinical Care of Strongyloides. Screening considerations. www.cdc.gov/strongyloides/hcp/clinical-care/index.html
-
WHO. Workload Indicators of Staffing Need (WISN). Includes the 2023 revised user manual. www.who.int/tools/wisn
-
WHO (2015). Malaria microscopy quality assurance manual, Version 2. www.who.int/docs/default-source/documents/publications/gmp/malaria-microscopy-quality-assurance-manual.pdf
-
WHO (2025). WHO information notice for users of malaria IVDs 2025/1. 31 March 2025. www.who.int/news/item/31-03-2025-who-information-notice-for-users-of-malaria-ivds-2025-1
-
WHO (2026). Electricity in health-care facilities. 14 October 2026; underlying national surveys from 2015–2022. www.who.int/news-room/fact-sheets/detail/electricity-in-health-care-facilities
-
WHO and UNICEF (2025). Countries making unprecedented efforts, but billions still lack basic services in health care facilities—WHO/UNICEF new report warns. 24 September 2025; estimates for 2023. www.who.int/news/item/24-09-2025-countries-making-unprecedented-efforts-but-billions-still-lack-basic-services-in-health-care-facilities—who-unicef-new-report-warns
-
WHO (2020). Laboratory biosafety manual, 4th edition. www.who.int/publications/i/item/9789240011311
-
WHO (2016). Use, care and maintenance of microscopes. Malaria microscopy SOP 12. www.who.int/publications/i/item/HTM-GMP-MM-SOP-12
-
WHO (2017). Guidance for procurement of in vitro diagnostics and related laboratory items and equipment. www.who.int/publications/i/item/9789241512558
-
WHO. Laboratory Quality Stepwise Implementation: Make an inventory of all supplies, their specifications and the suppliers. extranet.who.int/lqsi/node/136
-
WHO Global Malaria Programme. Selecting and procuring malaria RDTs. www.who.int/teams/global-malaria-programme/case-management/diagnosis/rapid-diagnostic-tests/selection-and-procurement
-
WHO. IHR Benchmarks: National laboratory system. Specimen referral and transport; laboratory networks. ihrbenchmark.who.int/document/9-national-laboratory-system?locale=en
-
Worrell CM et al. (2015). Cost Analysis of Tests for the Detection of Schistosoma mansoni Infection in Children in Western Kenya. American Journal of Tropical Medicine and Hygiene, 92, 1233–1239. pubmed.ncbi.nlm.nih.gov/25870422/
-
WHO (2022). WHO guideline on control and elimination of human schistosomiasis. www.who.int/publications/i/item/9789240041608
-
WHO. Laboratory Quality Stepwise Implementation: Checklist—Process Management. extranet.who.int/lqsi/checklist/13
-
DIDIDI. Project description. Published work-package plans. www.dididi.eu/project/project-description
-
WHO Regional Office for Africa. Health Financing. Includes regional expenditure data for 2022. www.afro.who.int/health-topics/health-financing